Supernus Pharmaceuticals Inc (SUPN) : Wilshire Associates Inc has sold out all of its stake in Supernus Pharmaceuticals Inc during the most recent quarter, according to the disclosure filed by the company on Aug 15, 2016 with the SEC. The investment management company has sold out 36,500 shares of Supernus Pharmaceuticals Inc which is valued at $827,820.
Other Hedge Funds, Including , Everpoint Asset Management boosted its stake in SUPN in the latest quarter, The investment management firm added 80,000 additional shares and now holds a total of 330,000 shares of Supernus Pharmaceuticals Inc which is valued at $7,484,400. Supernus Pharmaceuticals Inc makes up approx 0.20% of Everpoint Asset Management’s portfolio.Nicholas Investment Partners Lp boosted its stake in SUPN in the latest quarter, The investment management firm added 6,253 additional shares and now holds a total of 136,776 shares of Supernus Pharmaceuticals Inc which is valued at $3,102,080. Supernus Pharmaceuticals Inc makes up approx 0.27% of Nicholas Investment Partners Lp’s portfolio. Marshall Wace Llp sold out all of its stake in SUPN during the most recent quarter. The investment firm sold 31,747 shares of SUPN which is valued $720,022. Shell Asset Management Co added SUPN to its portfolio by purchasing 57,411 company shares during the most recent quarter which is valued at $1,267,061. Supernus Pharmaceuticals Inc makes up approx 0.03% of Shell Asset Management Co’s portfolio.
Supernus Pharmaceuticals Inc opened for trading at $21.47 and hit $22.12 on the upside on Thursday, eventually ending the session at $22.03, with a gain of 3.04% or 0.65 points. The heightened volatility saw the trading volume jump to 4,90,556 shares. Company has a market cap of $1,091 M.
On the company’s financial health, Supernus Pharmaceuticals Inc reported $0.18 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.13. The company had revenue of $50.40 million for the quarter, compared to analysts expectations of $49.71 million. The company’s revenue was up 43.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.03 EPS.
Many Wall Street Analysts have commented on Supernus Pharmaceuticals Inc. Supernus Pharmaceuticals Inc was Downgraded by Piper Jaffray to ” Neutral” on Jul 18, 2016. Supernus Pharmaceuticals Inc was Downgraded by Northland Capital to ” Market Perform” on Jul 18, 2016.
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing products for the treatment of central nervous system diseases. The Company launched its two products in neurology for the treatment of epilepsy which include Oxtellar XR and Trokendi XR. It is also engaged in developing multiple product candidates in psychiatry to address the medical needs and market opportunities in impulsive aggression across several areas (such as attention deficit hyperactivity disorder (ADHD) autism and bipolar disorder) and ADHD. The Company markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States. Its neurology portfolio consists of Oxtellar XR and Trokendi XR which are indicated for epilepsy in the United States. Its product candidates include Oxtellar XR Trokendi XR SPN-810 SPN-812 and SPN-809.